glp-1 shortage over FDA's decision kicks off 'unprecedented' tussle GLP-1 Weight-Loss Drugs Off Shortage

The full analysis set of all randomized individuals and the safety analysis set (all individuals receiving at least one dose of trial product) were the same and therefore used for all efficacy and safety evaluations

Archived from the original on 24 February 2022

Everything in this section is extrapolation based on the mechanism of action and user-reported outcomes

The metabolic improvements associated with GLP-1 agonist therapyincluding weight loss, improved glycaemic control, and potential benefits in MASLD (formerly known as non-alcoholic fatty liver disease)could address multiple health concerns simultaneously, though effects specifically in alcohol-related liver disease are not established